Objective: To determine the effects of pain and opioid pain medication use on clinical and functional outcomes in 1004 primary care patients with an anxiety disorder randomized to receive the Coordinated Anxiety Learning and Management (CALM) collaborative care intervention (cognitive-behavioral therapy and/or medication) versus usual care.
P ain problems that prompt medical care seeking or disability occur commonly in individuals with depressive 1 and anxiety 2 disorders. Several controlled observational analyses have shown that pain symptoms predict poorer outcome for patients receiving treatment for depression, [3] [4] [5] but ability to determine differential effects on treatment outcome (a prescriptive or moderator rather than predictive effect 6 ) is limited without a placebo or usual care (UC) comparator. Despite this extensively documented association between pain and depression, only 5 randomized controlled trials [7] [8] [9] [10] [11] have examined the moderating effect of pain symptoms on dichotomous treatment outcomes (ie, response or remission) in depression or anxiety.
Two studies examined the effects of pain on depression outcomes after treatment with duloxetine or placebo. One study showed comparable effects of duloxetine in patients with and without pain, 8 whereas the second showed that patients with pain had a better response to duloxetine than patients without pain. 7 Two studies examined the effects of pain on depression outcomes with a UC control condition. Whereas one study found that pain selectively predicted poorer intervention outcome in a collaborative care study of geriatric depression, 11 the second study found that pain predicted worse outcome in both intervention and UC conditions. 9 A recent study examined the effects of pain on anxiety outcomes in a collaborative care treatment study and also found worse anxiety outcomes in those anxious patients reporting higher pain, regardless of whether they were in the intervention or UC condition. 10 That study also examined continuous symptom changes over time and found that those with higher pain receiving the intervention had greater relative improvement than the UC group, although this improvement was insufficient for them to "catch up" and achieve equivalent rates of response or remission.
Even fewer studies have focused on the impact of pain medications on depressive and anxiety outcomes. Over the past decade, there has been a great increase in the use of prescription opioid medications for non-cancer-related pain conditions. 12 A number of studies have shown that use of prescription opioid medications is more common in patients with depression and anxiety disorders than in patients without these conditions. 13, 14 Thus, patients with pain and depression or anxiety are more likely to be taking prescription opioids. Small studies in selected populations have suggested that methadone, buprenorphine, tramadol, morphine, and other opioids may be effective for the treatment of anxiety and depression, 15 but the impact of concurrent opioid treatment has not been established.
In this report, we examine the predictive and prescriptive effects of pain interference and use of prescription opioid medication at baseline, on anxiety symptoms, and related disability outcomes in 1004 patients with one of 4 anxiety disorders participating in a multisite randomized controlled trial of collaborative care (the Coordinated Anxiety Learning and Management [CALM] study). 16 We hypothesized that pain and use of prescription opioid medication would predict worse outcomes, but that there would be no moderating effect of either variable on the intervention. We also performed secondary analyses in the large subgroup of anxious patients who had comorbid major depression, using depression rather than anxiety as an outcome. Finally, to elucidate the role of prescription opioid use only in those anxious patients with pain interference (ie, those patients potentially in need of pain medication), we repeated analyses in this subgroup only, comparing anxiety and disability outcomes in those using and not using prescription opioids.
METHODS

Setting, Participants, and Design
Between June 2006 and April 2008, 1004 primary care patients, 18 to 75 years old, receiving care at one of the 17 clinics in Little Rock, Los Angeles County, San Diego, and Seattle, and meeting DSM-IV criteria for panic disorder, generalized anxiety disorder, social anxiety disorder, and/or posttraumatic stress disorder were enrolled in the CALM study. Primary care providers and clinic nursing staff referred all potential participants, facilitated by an optional 5 question anxiety screener. 17 To determine eligibility, referred participants were administered the Mini International Neuropsychiatric Interview 18 by a specially trained master's level (social work, nursing, or psychologist) clinician, the Anxiety Clinical Specialist (ACS).
Cooccurring major depression was permitted. Persons unlikely to benefit from CALM (ie, persons with unstable medical conditions, marked cognitive impairment, active suicidal intent or plan, psychosis, bipolar I disorder, substance abuse, or dependence except for alcohol and marijuana abuse) were excluded. All participants gave informed, written consent for the study, which was approved by each institution's Institutional Review Board. After a baseline interview (see below) participants were randomized to CALM or UC for 1 year, using an automated computer program at RAND, where all posteligibility assessments were conducted by phone.
Intervention (CALM)/UC
CALM used a web-based monitoring system 19 modeled on the IMPACT intervention 20 with newly developed anxiety content and a computer-assisted cognitive-behavioral therapy (CBT) program that guided the patient and clinician. 21 CALM patients initially received their preferred course of treatment, either medication, CBT, or both, over 10 to 12 weeks. CBT was administered by the ACS (typically in 6 to 8 weekly sessions), whereas medication was prescribed by the primary care physician. A local study psychiatrist provided single-session medication management training to providers using a simple algorithm, 22 as needed consultation by phone or e-mail, and very rarely, a face-to-face assessment for complex or treatment refractory patients.
The ACS tracked patient outcomes on a web-based system by entering scores for the Overall Anxiety Severity and Impairment Scale (OASIS) 23 and a 3-item version of the Patient Health Questionnaire-9 (PHQ-9) and examining graphical progress over time. The goal was either clinical remission, defined as an OASIS < 5 = "mild," sufficient improvement such that the patient did not want further treatment, or improvement with residual symptoms or other emergent problems requiring a nonprotocol psychotherapy (ie, dialectical behavior therapy, family or dynamic psychotherapy). Symptomatic patients thought to benefit from additional treatment with CBT or medication could receive more of the same modality (stepping up) or the alternative modality (stepping over), over the next 9 months. After treatment completion, patients were entered into "continued care" and received monthly follow-up phone calls to reinforce CBT skills and/or medication adherence for the remainder of the year. All ACSs received weekly supervision from a psychiatrist and psychologist. Of 503 patients randomized to CALM, 482 received treatment; 166 (34%) had only CBT visits; 43 (9%) had only medication visits; and 273 (57%) had both. The majority (424 or 88%) had all visits completed by 6 months.
UC patients continued to be treated by their physician in the usual manner, that is, with medication, counseling (7 of 17 clinics had limited in-clinic mental health resources, usually a single provider with limited familiarity with evidence-based psychotherapy 24 ), or referral to a mental health specialist. After the eligibility diagnostic interview, the only contact UC patients had with study personnel was for assessment by phone.
Assessments
The assessment battery was administered at baseline, 6, 12, and 18 months through centralized phone survey by the RAND Survey Research Group who were blinded to treatment assignment. The primary outcome was a generic measure of 2 key components of all anxiety disorders, psychic and somatic anxiety: the Brief Symptom Inventory 12-item subscale for anxiety and somatization (BSI-12). 25 Response was defined as a Z50% reduction on the BSI-12, or meeting the definition of remission, and remission was defined as a face-valid per item score of <0.5 (between "none" and "mild," total BSI-12 score <6), consistent with previous analyses using the BSI for depression outcomes. 26 Secondary measures included depression (8-item version of the PHQ-9 27 ) and functional status (Sheehan Disability 28 and SF-12 29 ). The single pain item on the SF-12 was used to determine baseline pain status, as previously described. 9, 11 Patients were dichotomized into those with no or limited pain interference ("not at all" or "a little bit") versus those with pain interference ("moderate," "quite a bit," or "a lot"). Self-reported use of medication at baseline was obtained by telephone survey interviewers who requested that patients get their pill bottles and read the names of each medication they were taking. It was used to dichotomize patients into those taking prescription opioid medication versus those not taking prescription opioid medication.
Analysis
We compared demographics and baseline anxiety and depression disorder and symptom rates by pain and opioid medication group using t tests and w 2 tests for continuous and categorical variables, respectively. To estimate the effect of baseline pain status or opioid medication status over time, we jointly modeled the outcomes at the 4 assessment times (baseline and 3 follow-ups at 6, 12, and 18 mo) by intervention status, time, pain, or opioid subgroup (controlling for the other subgroup), and the interaction of intervention, time and pain or opioid subgroup, and site. In models where the 3-way interaction was nonsignificant, we refit the model including 2-way interactions of pain or opioid subgroup with wave and intervention with wave, dropping the 3-way interactions. Time was treated as a categorical variable. To avoid restrictive assumptions, the covariance of the outcomes at the 4 assessment times was left unstructured. We fitted the proposed model using a restricted maximum likelihood approach, which produces valid estimates under the missingat-random assumption. 30 This approach correctly handles the additional uncertainty arising from missing data and uses all available data to obtain unbiased estimates for model parameters. 31 This is an efficient way for conducting an intent-to-treat analysis, because it includes all the participants with a baseline assessment. Our principal analysis focused on the entire sample and 2 outcomes: BSI-12 anxiety score and Sheehan Disability score. Also, we repeated these analyses for the subgroup of patients who met criteria for major depression, using PHQ-8 and Sheehan Disability scores as outcomes. Finally, to clarify the role of prescription opioid use in those with pain interference, we performed analyses on the subgroup of patients with high pain interference and examined the effects of prescription opioid use versus no use in this cohort. For cross-sectional analyses, we used attrition weights to correctly account for participants who missed 1 or more follow-up assessments. The statistical software used was SAS version 9 (SAS Institute Inc., Cary, NC). All P values were 2-tailed, and we adopted a conservative significance level of P < 0.01 to account for multiple comparisons. P values between 0.05 and 0.01 are interpreted as hypothesis generating and heuristic, rather than definitive.
RESULTS
There were 45% (441 of 1004) of patients endorsing at least moderate pain interference and 8.5% (86 of the 1004) of patients taking prescription opioid medication at baseline. Patients with moderate pain interference, compared with those with mild or no pain interference, were older and more medically ill, were less educated and less likely to be privately insured, and more likely to be female, African American, and to have posttraumatic stress disorder and comorbid depression ( Table 1 ). The findings were somewhat similar when comparing the smaller group of patients taking opioid medication in the prior 6 months with those not taking opioid medication, except that there were no sex, education, or ethnicity effects ( Table 2 ). Patients endorsing pain interference were significantly more likely to be taking prescription opioid medication than those without pain interference (16% vs. 2%) and patients taking opioid medication were significantly more likely to endorse at least moderate pain interference (83% vs. 40%).
Wald tests for 3-way interactions in each of the models were nonsignificant. Patients with baseline pain interference had higher anxiety scores (t = 11.58, P < 0.001) and greater disability (t = 7.77, P < 0.001) at baseline. Over the 18-month study, patients with baseline pain interference wResponse defined as Z50% reduction on the BSI-12, with all those in remission considered to have responded.
zRemission defined as a per item BSI-12 score of <0.5 (total score <6). BSI-12 indicates Brief Symptom Inventory 12-item anxiety subscale; CI, confidence interval. tended to show greater decreases in anxiety than those without baseline pain interference at all 3 follow-up waves (Wald F = 3.77, df = 990, P = 0.0105), controlling for baseline opioid status (Fig. 1 ). They did not show differences in decreases in disability (Wald F = 0.84, df = 990, P = 0.47).
Patients taking prescription opioid medication had higher anxiety scores (t = 3.43, P < 0.001) and greater disability (t = 2.21, P = 0.028) at baseline. Over the 18-month study, decreases in anxiety symptoms (Wald F = 0.84, df = 990, P = 0.47) ( Fig. 2) and disability (Wald F = 1.23, df = 990, P = 0.29) were no different in this subgroup compared with patients not taking prescription opioid medication.
In contrast to the above analyses of continuous scores, categorical analyses comparing patients with pain interference with those without pain interference showed significantly lower response and remission rates at all 3 outcome windows (6, 12, and 18 mo) ( Table 3 ). The results were less consistent when patients taking opioid medication were compared with those not taking opioid medication. Response rates for patients taking opioid medications were significantly lower at only 2 time points, and remission rates were only lower at the 12-month time point (Table 4 ). There was no significant interaction (P < 0.01) with intervention received.
We repeated the above analyses for the subgroup of patients with major depression, using PHQ-8 as the outcome measure. In these analyses, Wald tests for 3-way interactions were nonsignificant. In patients with major depression, the group with pain interference at baseline had higher PHQ-8 (t = 5.71, P < 0.001) and Sheehan Disability scores (t = 5.53, P < 0.001) at baseline that remained worse at each of the subsequent time points. When patients with major depression were divided according to those taking and not taking prescription opioids at baseline, the results were similar for PHQ-8 outcomes (prescription opioid users at baseline were more depressed at baseline (t = 3.16, P = 0.002) and remained more depressed over time). In contrast, for Sheehan Disability, patients taking prescription opioids at baseline (who had comparable disability scores to those not taking prescription opioids) showed a trend for less disability improvement over time (Wald F = 2.80, df = 634, P = 0.039) than those not taking prescription opioids (Fig. 3) .
Finally, we examined separately the subgroup of patients with pain interference and compared outcomes in those taking (n = 71) and not taking (n = 370) opioid medications. The 3-way interaction effect for use of prescription opioids on Sheehan Disability over time was not significant, but there was a trend for 3-way interaction for BSI-12 anxiety (Wald F = 2.61, df = 427, P = 0.051). The intervention seemed to lose its beneficial effect at 18 months in those using prescription opioids (Fig. 4 ). These last analyses should be seen as exploratory given the smaller sample size and the small number of patients taking opioid medications.
DISCUSSION
These findings show that patients with pain interference at baseline and patients taking prescription opioid medication at baseline are more severely ill, reporting higher anxiety, depression, and disability scores. Although the groups did not respond differently to treatment on continuous measures of anxiety, patients with pain interference (compared with those without pain interference) and those taking prescription opioid medication (compared with those not taking opioid medication) were less likely to respond (ie, show a 50% decrease in their BSI anxiety score) or remit (ie, <6 on their BSI anxiety score). Thus, even though the average decrease in anxiety symptoms over time was somewhat greater in patients with pain disability at baseline, it was not sufficient to "catch up" to produce equivalent response or remission rates at either 6, 12, or 18 months. The comparison of response and remission rates in patients taking opioid versus those not taking opioids produced less consistent results, possibly because the sample size had reduced power to detect effects of interest, or because baseline users may not have continued use, whereas other baseline nonusers may have begun use. Specifically, response rate differences only occurred at 6 and 18 months and remission rate differences only occurred at 12 months. These categorical analyses cannot control for baseline differences on the BSI anxiety subscale score used to compute these categorical measures.
There was no evidence that the CALM collaborative care intervention was more or less effective in patients with 
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baseline pain interference or in patients taking prescription opioid medication. Thus, neither pain nor opioid medication use seemed to selectively moderate the effect of the intervention, consistent with our hypothesis. These findings are consistent with the notion that these 2 subgroupings are not mutually exclusive and constitute 2 different ways to measure distress and disability resulting from pain. Opioid use may be a marker for more severe pain or other disabling medical comorbidity. Secondary analyses revealed some interesting findings regarding the potential adverse effects of use of prescription opioid medication on anxiety outcome. This potential effect is much more circumscribed than the broader set of adverse clinical effects recently shown to be present in returning veterans with opioid use that is more extensive in duration, dose and potency. 32 This question was not an a priori focus of the CALM study and so, the findings must be viewed as tentative. In the subgroup of patients with major depression, those taking prescription opioid medication showed a borderline significant trend for less disability improvement over time, compared with those not taking prescription opioids at baseline. Although this finding fell short statistically (by failing to meet P < 0.01), it suggests that chronic prescription opioid medication might be associated with worse depression outcomes. Interestingly, negative affects like anxiety and depression seem to predict worse opioid effects on pain. 33 Finally, when we examined the effect of opioid medication use on outcomes in patients reporting high pain interference, the beneficial effect of the intervention on symptoms of anxiety, which was clearly evident at the 6-and 12-month time points (during which treatment was still active), was not sustained at 18 months (6 mo after treatment had ceased). These latter data point to the possibility of an association between prescription opioid use and less than optimal effectiveness of mental health treatment, but more data are required to confirm this association. However, although self-reports of medication use are reasonably valid, 34 self-reports of opioid use are less often validated than reports of other medication use, 35 and use in many of these participants may have been intermittent and not consistent over the 18-month course of the study. Thus, this 18-month finding must be viewed as very tentative.
An important clinical question is the degree to which treating pain improves (or impedes) patients' responsiveness to psychological treatments. It is important to note that our measure of pain is a single self-report item that was not validated by other more objective observations. Nonetheless, we did not find evidence that prescription opioid treatment improves response to anxiety treatment; in fact, the results suggested either a neutral or deleterious effect. This is relevant to clinical care because patients with pain often attribute their anxiety and depression to their pain problem: "If you treat my pain, my anxiety/depression will get better." Rather, our data suggest that opioid treatment may retard responsiveness to anxiety treatment or make it less enduring. These findings were marginally significant and found only in subsets of the CALM treatment population. Thus, they need to be replicated in a larger study that examines this question specifically. Also, conceivably, patients receiving prescription opioids for their pain may have had more severe pain and/or other medical factors that contributed to their poorer outcomes.
In summary, in a large, primary care sample of patients with anxiety disorders, although comorbid pain interference does not necessarily impede response to treatment, it is associated with reduced likelihood of achieving response or remission with treatment. Also, prescription opioid use among those with pain interference, and possibly those with comorbid major depression, is unlikely to improve-and may even retard-response to treatment, although this hypothesis needs to be further explored in subsequent controlled studies.
